JenniferAngChanMD
Hematology • Boston, MAHematologic Oncology
Instructor in Medicine, Dana-Farber Cancer Institute
Dr. Chan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-6315Fax+1 617-632-5370- Is this information wrong?
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2003 - 2006- Brigham and Women's HospitalResidency, Internal Medicine, 2000 - 2003
Harvard Medical SchoolClass of 2000
Certifications & Licensure
MA State Medical License 2003 - 2026
NH State Medical License 2023 - 2025- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer Start of enrollment: 2005 Jul 01
- RAD001 and Temozolomide in Patients With Advanced Pancreatic Neuroendocrine Tumors Start of enrollment: 2008 May 01
- Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors Start of enrollment: 2008 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Biomarkers of pembrolizumab efficacy in advanced anal squamous cell carcinoma: analysis of a phase II clinical trial and a cohort of long-term responders.Huffman, B., Singh, H., Ali, L., Horick, N., Wang, S., Hoffman, M., Metayer, K., Murray, S., Bird, A., Abrams, T., Biller, L., Chan, J., Meyerhardt, J., McCleary, N., ...> ;Journal for Immunotherapy of Cancer. 2024 Jan 25
- Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide sub...Singh, S., Ferone, D., Capdevila, J., de Herder, W., Mailman, J., Hellström, L., Liedman, H., Svedberg, A., Tiberg, F., Chan, J., Halperin, D.> ;Trials. 2024 Jan 16
- 1 citationsIntertumoral lineage diversity and immunosuppressive transcriptional programs in well-differentiated gastroenteropancreatic neuroendocrine tumors.Samantha E Hoffman, Todd W Dowrey, Carlos Villacorta Martin, Kevin Bi, Breanna Titchen, Shreya Johri, Laura DelloStritto, Miraj Patel, Colin Mackichan, Stephanie Inga,...> ;Science Advances. 2023 Sep 29
- Join now to see all
Other
- Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growthChan JA, Kulke M
http://www.uptodate.com/contents/metastatic-gastroenteropancreatic-neuroendocrine-tumors-local-optio
UpToDate, Wolters Kluwer Health - 2013-04-15 - Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoringChan JA, Kulke M
http://www.uptodate.com/contents/metastatic-gastroenteropancreatic-neuroendocrine-tumors-presentatio
UpToDate, Wolters Kluwer Health - 2012-07-05 - Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretionChan JA, Kulke M
http://www.uptodate.com/contents/metastatic-gastroenteropancreatic-neuroendocrine-tumors-systemic-th
UpToDate, Wolters Kluwer Health - 2013-02-05
Professional Memberships
- Member
Hospital Affiliations
Dana-Farber Cancer InstituteBoston, Massachusetts
Brigham and Women's HospitalBoston, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
